Image of the Month
Osteoblastic Response in Patients with Non-small Cell Lung Cancer with Activating EGFR Mutations and Bone Metastases during Treatment with EGFR Kinase Inhibitors

https://doi.org/10.1097/JTO.0b013e3181cf32aaGet rights and content
Under an Elsevier user license
open archive

Keywords

NSCLC
Bone metastasis
EGFR mutation
Tyrosine kinase inhibitor

Cited by (0)

Roman Thomas received research support from AstraZeneca and lecture fees from Roche; Sascha Ansén, Lucia Nogová, Matthias Scheffler, Zander Töpelt, Jürgen Wolf received research support and served as a consultant to Roche and AstraZeneca.

Copyright © 2010 International Association for the Study of Lung Cancer. All rights reserved.